Scarica l'app Stockscreener
6.35
5.93%
-0.40
Pre-mercato:
6.38
0.03
+0.47%
Regenxbio Inc Borsa (RGNX) Ultime notizie
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace
RGNX stock on track for worst day ever as big Q1 loss, cash concerns eclipse Duchenne trial success - MSN
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
REGENXBIO to push for accelerated approval of DMD gene therapy - MSN
RGNX: Rolling BLA for Duchenne gene therapy set for Q3 2024, with robust data and regulatory momentum - TradingView
Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway - Insider Monkey
RegenXbio’s RGX-202 Pivotal Win Lifts Outlook - TipRanks
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2026 Earnings Call Transcript - Insider Monkey
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
RegenXBio’s Earnings Call Signals Pivotal Gene-Therapy Win - TipRanks
REGENXBIO to Participate in Upcoming Investor Conferences - marketscreener.com
Biotech REGENXBIO lines up May investor talks in New York and online - Stock Titan
Gene therapy innovation gains momentum at REGENXBIO during ASGCTherapy event - Traders Union
Regenxbio slides after late-stage trial data for Duchenne therapy - MSN
StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate - Genetic Engineering and Biotechnology News
What's Behind Regenxbio's Recent Plunge - Kavout
REGENXBIO Inc stock (US75901B1052): gene therapy pipeline in focus after recent data update - AD HOC NEWS
REGENXBIO: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results (NASDAQ:RGNX) - Seeking Alpha
RegenXBio (RGNX) Gets a Buy from RBC Capital - The Globe and Mail
RGNX Technical Analysis & Stock Price Forecast - Intellectia AI
RGNX Maintained by B of A Securities -- Price Target Lowered to $14 - GuruFocus
Bank of America Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - MarketBeat
Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says - Moomoo
REGENXBIO Is Maintained at Overweight by Barclays - Moomoo
RGNX Maintained by Barclays -- Price Target Lowered to $12 - GuruFocus
A Quick Look at Today's Ratings for Regenxbio(RGNX.US), With a Forecast Between $12 to $42 - Moomoo
Goldman Sachs Maintains Regenxbio(RGNX.US) With Hold Rating, Cuts Target Price to $10 - Moomoo
Nasdaq Jumps Over 200 Points; Dillard's Shares Gain After Q1 Earnings - Sahm
Discipline and Rules-Based Execution in RGNX Response - Stock Traders Daily
Barclays Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval - Sahm
Goldman Sachs lowers Regenxbio stock price target on regulatory uncertainty - Investing.com
Goldman Sachs lowers Regenxbio stock price target on regulatory uncertainty By Investing.com - Investing.com Canada
Regenxbio posts mixed Phase III data on RGX-202 - The Pharma Letter
Regenxbio Inc (RGNX) Q1 2026 Earnings Call Highlights: Promising RGX-202 Results and Path to FDA Approval - GuruFocus
REGENXBIO (RGNX) Reports Positive Data from RGX-202 Trial - GuruFocus
Regenxbio (RGNX) Q1 Loss Deepens And Reinforces Bearish Cash Runway Concerns - simplywall.st
REGENXBIO advances Duchenne gene therapy toward accelerated approval - MSN
REGENXBIO 1Q Loss/Shr $1.72 >RGNX - Moomoo
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):